文献速递胸部肿瘤

免疫治疗革命性改变非小细胞肺癌治疗:结果、前景与新挑战

Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
PubMed 文献 · Eur J Cancer · 2017-04-11

免疫检查点抑制剂(ICI)靶向PD1/PDL1等通路改善抗肿瘤免疫。Keynote-024中帕博利珠单抗一线治疗PDL1≥50%肿瘤较化疗延长中位无进展生存期(10.4个月 vs 6.0个月,HR=0.50)且提高客观缓解率(45% vs 28%)。Checkmate-026中纳武利尤单抗对比铂类化疗未见获益。阿特珠单抗二线治疗较多西他赛延长中位总生存期(13.8个月 vs 9.6个月)。

要点

  • 帕博利珠单抗一线治疗PDL1≥50%的晚期非小细胞肺癌优于化疗。
  • 纳武利尤单抗对比铂类化疗在PDL1≥5%人群未见获益,PDL1≥50%亚组亦无获益。
  • 阿特珠单抗二线治疗较多西他赛延长中位总生存期(13.8个月 vs 9.6个月)。

核心结论

  • 这些结果提示晚期非小细胞肺癌治疗的新范式:帕博利珠单抗用于PDL1≥50%肿瘤的一线治疗。

研究设计与样本

  • 本文为综述,汇总近期评估免疫检查点抑制剂的II期和III期随机试验结果。

主要发现

  • Keynote-024中帕博利珠单抗一线治疗PDL1≥50%肿瘤(占筛查肿瘤的30%)中位无进展生存期10.4个月 vs 化疗6.0个月(HR=0.50;95%CI 0.37-0.68,P<0.001),客观缓解率45% vs 化疗28%(P=0.0011),1年总生存率约70%。
  • Checkmate-026中纳武利尤单抗对比标准化铂类化疗,PDL1≥5%人群的中位无进展生存期4.2个月(纳武利尤单抗)vs 5.9个月(化疗;HR=1.15;95%CI 0.91-1.45,P=0.25),PDL1≥50%亚组亦未见获益。
  • Keynote-021中帕博利珠单抗联合化疗一线治疗未经选择的非小细胞肺癌,客观缓解率55% vs 单纯化疗29%(P=0.0016)。
  • OAK III期研究中阿特珠单抗二线治疗对比多西他赛,中位总生存期13.8个月 vs 多西他赛9.6个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to improve anti-tumour immune responses. Until recently, nivolumab was the only ICI validated for advanced non-small-cell lung cancer (NSCLC) in a second-line treatment setting. Results from recent phase II and phase III randomised trials testing other ICIs have been presented. In Keynote-024, pembrolizumab, an anti-PD1 antibody, was reported to have great efficacy in the first-line treatment of PDL1 ≥ 50% tumours (30% of screened tumours), with a progression-free survival (PFS, median) of 10.4 months versus 6.0 months with chemotherapy (CT; hazard ratio [HR] = 0.50; 95% confidence interval [95% CI] 0.37-0.68, P < 0.001), overall response rate (ORR) of 45% versus 28% with CT (P = 0.0011), and a 1-year overall survival (OS) of around 70%. In contrast, Checkmate-026 reported that nivolumab failed to show any benefit compared with standard platinum-based CT, with a PFS (median) in the PDL1 ≥ 5% NSCLC group of 4.2 months (nivolumab) versus 5.9 months (CT; HR = 1.15: 95% CI 0.91-1.45, P = 0.25). No benefit was observed in the PDL1 ≥ 50% subgroup. An encouraging report of the efficacy of pembrolizumab in addition to CT in first-line treatment in unselected NSCLC was also presented (Keynote-021) with an ORR of 55% versus 29% with CT alone (P = 0.0016). Atezolizumab, an anti-PDL1 antibody, showed efficacy for second-line treatment compared with docetaxel (OAK phase III study) with an OS (median) of 13.8 months versus 9.6 months with docetaxel. These results suggest a new paradigm for the treatment of advanced NSCLC using pembrolizumab for the first-line treatment of PDL1 ≥ 50% tumours.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Giroux Leprieur E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer. 2017. PMID: 28407528. doi:10.1016/j.ejca.2016.12.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。